Active	Status	Sponsor type	Region	Phase	Filter
6 Active 11 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Encelto (revakinagene taroretcel-lwey) / Neurotech Pharma
NCT03316300 / 2017-003234-82: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A	Completed	3	120	Europe, US, RoW	NT-501, Sham Procedure	Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited	Macular Telangiectasia Type 2 (MacTel)	08/22	09/22
NCT03319849 / 2017-003260-12: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B	Completed	3	119	Europe, US, RoW	NT-501, Sham	Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited	Macular Telangiectasia Type 2	08/22	09/22
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM	Recruiting	3	13	US	NT-501 CNTF Implant	Neurotech Pharmaceuticals	Macular Telangiectasia Type 2	04/26	07/26
NCT04729972: Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2	Completed	2	33	US, RoW	NT-501 CNTF implant	Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited	Macular Telangiectasia Type 2	12/22	12/22
NCT02862938 / 2011-004177-83: Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration	Active, not recruiting	2	54	US	NT-501 ECT implant, Sham	Stanford University	Glaucoma	08/25	12/25
NCT04577300: Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma	Recruiting	2	30	US	NT-501, Sham comparator	Stanford University	Glaucoma	08/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Encelto (revakinagene taroretcel-lwey) / Neurotech Pharma
NCT03316300 / 2017-003234-82: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A	Completed	3	120	Europe, US, RoW	NT-501, Sham Procedure	Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited	Macular Telangiectasia Type 2 (MacTel)	08/22	09/22
NCT03319849 / 2017-003260-12: A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B	Completed	3	119	Europe, US, RoW	NT-501, Sham	Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited	Macular Telangiectasia Type 2	08/22	09/22
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM	Recruiting	3	13	US	NT-501 CNTF Implant	Neurotech Pharmaceuticals	Macular Telangiectasia Type 2	04/26	07/26
NCT04729972: Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2	Completed	2	33	US, RoW	NT-501 CNTF implant	Neurotech Pharmaceuticals, The Lowy Medical Research Institute Limited	Macular Telangiectasia Type 2	12/22	12/22
NCT02862938 / 2011-004177-83: Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration	Active, not recruiting	2	54	US	NT-501 ECT implant, Sham	Stanford University	Glaucoma	08/25	12/25
NCT04577300: Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma	Recruiting	2	30	US	NT-501, Sham comparator	Stanford University	Glaucoma	08/25	12/25